FTC calls for more info on Pfizer/Wyeth deal

Global drug giant Pfizer has received a request for additional information from the US Federal Trade Commission with respect to its  previously-announced, $68.0-billion proposed acquisition of Wyeth  (Marketletters passim). The request was anticipated as part of the  regulatory process under the Hart-Scott-Rodino Antitrust Improvements  Act.

Pfizer intends to respond expeditiously to this request. Completion of  the transaction remains subject to the expiration of the waiting period  under the HSR Act, governmental and regulatory approvals in certain  other jurisdictions, approval by the stockholders of Wyeth, the  satisfaction of certain conditions related to the debt financing for the  transaction, and other usual and customary closing conditions. Pfizer  and Wyeth continue to expect the transaction to close at the end of the  third quarter or during the fourth quarter of this year.